Prophylactic glucocorticoids are widely used to modulate the inflammatory response and treat presumed relative adrenal insufficiency in children undergoing heart surgery. There is wide variability between centre and physician's preference in the timing, dose, route or type of steroid to be administered. There is an intense debate about prophylactic steroid use and their effect on the clinical outcomes. The weight of the current evidence for prophylactic, perioperative steroid administration suggests they do not unequivocally improve clinical endpoints. A large, multicentre prospective randomized controlled trial is needed to clarify the role of steroids in paediatric heart surgery. 
Introduction
A best evidence topic was constructed according to a structured protocol. This is fully described in a previous publication in the IJS( [1] ).
Three-part question
In neonates undergoing heart surgery with cardiopulmonary by-pass (CPB) is prophylactic use of perioperative steroids associated with better clinical outcomes?
Clinical scenario
You are the registrar scrubbing for an arterial switch operation in a 14 days old neonate. You notice the anaesthetist administering dexamethasone before induction. The consultant explains that he gives steroids in all neonates to suppress systemic inflammatory response and prevent effects of potential adrenal insufficiency. However, you scrubbed in similar cases and other anaesthetists do not give steroids at all. You ask yourself if the use of perioperative steroids improves clinical outcomes following heart surgery in neonates? You resolve to check the literature yourself.
Search strategy
Medline database using PubMed interface, search field: title/ abstract.
"(steroid OR corticosteroid OR methylprednisolone OR dexamethasone OR hydrocortisone) AND (neonate OR neonatal OR children OR pediatric) AND (by-pass OR cardiopulmonary bypass OR cardiac surgery OR cardiac surgical procedure OR heart surgery OR congenital heart disease OR pediatric heart surgery)".
Search outcome
We found 194 papers using the reported search. From these, 8 papers were identified that provided the best evidence to answer the question. The main outcome of these papers are presented in Table 1 .
Results
This evidence review focuses on prophylactic, perioperative steroid regimes for neonatal cardiac surgery. The abrupt interruption of maternal corticotropin releasing factor and cortisol at parturition and the immaturity of the hypothalamic-pituitary axis have been related to the reduced ability of neonates to mount an adequate stress response [2] . There is no consensus in diagnosing adrenocortical insufficiency in children and correlation with clinical outcome is controversial [2] . Cardiac surgery with use of cardiopulmonary bypass (CPB) provokes a systemic inflammatory response. Steroids have been widely used to mitigate potential deleterious effects of systemic inflammation [3, 4] . However, the impact of steroids on clinical outcomes following neonatal heart surgery remains unclear.
We found only two randomized controlled trials assessing the effect of steroids versus no steroids on clinical outcomes [5, 6] in neonates. These trials had a small sample size and were single centre. The majority of the studies were retrospective, three of them being multicentre on large cohorts [3, 4, 7] . There was heterogeneity among the studies in the clinical outcomes measured. Most studies measured: early mortality, ventilator duration, infection rates, hyperglycaemia and insulin requirement, low cardiac output prevalence, fluid balance and intensive care unit (ICU) length of stay. Furthermore, we found variability in the type, dose and route of steroid regimen. This is similar to previous surveys of steroid use [8, 9] .
Keski-Nisula et al. [6] , randomized 40 neonates to either receiving methylprednisolone at induction or placebo. In the steroid group, blood glucose levels were significantly higher compared to placebo. There was no difference in early mortality, inotropic score, serum lactate, duration of ventilation or ICU stay.
Graham et al. [10] , randomized neonates to receive methylprednisolone as either 2-dose (n ¼ 39), being 8 h preoperatively and included to the CPB prime, or single dose (n ¼ 37) being included in the CPB prime only. The 2-dose steroid cohort had significantly higher serum creatinine and reduced diuresis. Mortality, infection rates, insulin requirements, inotropic requirement, fluid balance, duration of mechanical ventilation, ICU and hospital stay did not differ between the groups.
Robert et al. [5] , randomized 40 neonates undergoing cardiac surgery with CPB to either postoperative hydrocortisone infusion for 5 days (n ¼ 19) or placebo (n ¼ 21). The hydrocortisone group had improved fluid balance, urine output and inotropic score. No significant differences were found in: mortality, ventilator-free days, hospital length of stay, kidney function, antibiotic use for suspected infections or blood glucose levels.
Pasquali et al. [3] , in a multivariate analysis of the largest population to date: 46730 children (10018 neonates) undergoing cardiac surgery, compared outcomes between steroid recipients and non-recipients. In the neonatal analysis, steroids increased ICU stay and the use of insulin, however there were no differences in infection rates, duration of ventilation or early mortality.
Pasquali et al. [4] analysed steroid use in 3180 neonates undergoing heart surgery. There was no significant mortality or length of stay difference between any methylprednisolone regimens versus no steroids. The authors stratified the neonates using a risk score and performed subgroup analyses. The lower surgical risk group had a significant association with infection across all steroid regimens.
Elhoff et al. [7] , using data from a trial database, analysed outcomes following the Norwood procedure in neonates that received intraoperative steroids (n ¼ 498) compared to non-recipients (n ¼ 51). In the univariate analysis non steroid recipients had better survival but longer ICU and hospital stays. In multivariate analysis, hospital survival again trended toward favouring the nonsteroid group, while length of stays, ECMO, infection and renal failure rates no longer differed statistically.
Dreher et al. [11] compared outcomes from neonates undergoing heart surgery with (n ¼ 55) and without (n ¼ 58) methylprednisolone added to the CPB prime. There were no differences in clinical outcomes (including length of stay, ventilation requirement, infection and mortality) between both groups.
Ando et al. [12] enrolled 20 neonates undergoing biventricular repair. Ten neonates were assigned to receive either hydrocortisone infusion after bypass or placebo infusion. The placebo group had a reduction in the left ventricular shortening fraction, had higher inotropic requirements and lactate levels compared to the steroid groups. Furthermore, steroid supplementation was associated with less body oedema, higher blood oxygenation and shorter duration of ventilation. There was no difference in renal failure or blood glucose levels.
Clinical bottom line
The majority of the studies suggest that perioperative steroid use does not affect early mortality in neonates undergoing heart surgery. One large retrospective study highlighted increased infection in steroid recipients. A few small studies suggested perioperative steroids protected against low cardiac output syndrome and reduced fluid retention. One small study demonstrated reduced ventilation times and better oxygenation in the steroid group while the rest of the papers showed no difference. In two studies, steroid use increased ICU stay. One study suggested worsening of the renal function in the high dose steroid group. Given the weight of current evidence, prophylactic, perioperative steroid administration for neonatal heart surgery does not unequivocally improve clinical endpoints. A large, multicentre prospective randomized controlled trial is needed to clarify the role of steroids in paediatric heart surgery. (continued on next page) 
